United States Patent 7,906,519: Scope, Claims, and US Patent Landscape for Colchicine With Ritonavir in Familial Mediterranean Fever
What does US 7,906,519 claim, in plain claim-scope terms?
US 7,906,519 claims a specific combination-use regimen: a treatment method for Familial Mediterranean Fever (FMF) using colchicine, when the patient is also receiving ritonavir 200 mg/day, with a defined dose adjustment ceiling for colchicine that is lower than the “usual maximum” colchicine dose absent ritonavir.
Core claim elements (Claim 1)
Claim 1 is a method claim with these required limitations:
- Patient condition: “a patient in need of treatment for Familial Mediterranean Fever”
- Drug A: colchicine administered orally
- Drug B (concomitant): the patient is receiving ritonavir at 200 mg per day
- Dose-adjustment framework: the regimen uses an “adjusted daily dosage amount of colchicine”
- Hard ceiling value: the adjusted daily dosage is a maximum colchicine dosage amount of 0.6 mg colchicine per day
- Comparative reduction requirement: the adjusted maximum is “a reduction from an intended daily dosage amount of colchicine in the absence of concomitant ritonavir” with the table of usual maximums
The age-based “usual maximums” stated in the claim text
The claim includes an “absence of ritonavir” dosing table to define what the regimen is reduced from:
| Age group |
“Usual Maximum” colchicine per day |
“Usual Maximum” colchicine per day (as stated) |
| Adults and children >12 years |
1.2 mg |
2.4 mg |
| Children >6 to 12 years |
0.9 mg |
1.8 mg |
| Children 4 to 6 years |
0.3 mg |
1.8 mg |
Key scope point: even though the table lists multiple “usual maximum” amounts by age, the claim’s operative limitation for the ritonavir-concomitant regimen is a single maximum of 0.6 mg colchicine per day.
How broad is claim 1 across patients, dosing, and administration?
Patient selection breadth
- The patient category is limited by diagnosis: FMF.
- The claim does not add further biomarkers, severity criteria, genotype, or prior therapy requirements, so the patient population scope is limited primarily to FMF and eligibility for oral colchicine.
Concomitant ritonavir restriction
- The claim requires concomitant ritonavir at 200 mg/day.
- That number functions as a “hard” linkage: regimens using ritonavir doses other than 200 mg/day are outside claim 1 unless they are argued as literal equivalents (for infringement analysis) under applicable doctrine.
Colchicine dose restriction
- The claim’s key limiting phrase is “a maximum colchicine dosage amount of 0.6 mg per day.”
- This reads as an upper bound: to infringe, the adjusted daily dosage must be capped at 0.6 mg/day.
- The claim also requires the adjusted dose to be a reduction “from an intended daily dosage amount … in the absence of concomitant ritonavir,” which imports the comparison concept, even if infringement ultimately turns on whether the method uses the specified adjusted cap.
Oral route restriction
- Colchicine is required to be orally administered.
- Parenteral routes are excluded.
What is the practical claim scope for adults vs children?
The claim states a single maximum 0.6 mg/day in the presence of ritonavir 200 mg/day. The provided “absence of ritonavir” table includes higher usual maximums in adults and older children (up to 1.2 mg as one “usual maximum” value and 2.4 mg as a separate value within the claim text), with lower values for younger children.
Scope implication
- Adults and children >12 years: the ritonavir-concomitant maximum is 0.6 mg/day, which is below the listed usual maximum ranges absent ritonavir.
- Children >6 to 12 years: the ritonavir-concomitant maximum is also capped at 0.6 mg/day, regardless of whether the absence-of-ritonavir table values are lower or higher.
- Children 4 to 6 years: same ceiling, 0.6 mg/day, despite the claim’s table including values that are sometimes below 0.6 mg and sometimes above 0.6 mg (the text includes 0.3 mg and 1.8 mg entries).
Business read-across: For any product label or clinical protocol targeting FMF patients taking ritonavir 200 mg/day, the patent’s enforceable claim boundary centers on using colchicine with a maximum of 0.6 mg/day and framing that regimen as a reduced dose versus a no-ritonavir intended maximum.
What does this mean for “scope” of infringement risk?
Because the claim is a method-of-treatment claim tied to a specific concomitant dose and specific adjusted colchicine maximum, infringement risk clusters around:
- FMF patients treated with oral colchicine
- Patients concurrently receiving ritonavir specifically at 200 mg/day
- Protocols or prescribing instructions that set colchicine dosing at or below 0.6 mg/day as the adjusted maximum when ritonavir is 200 mg/day
Design-around pressure point: changing either (i) ritonavir dose away from 200 mg/day, or (ii) the colchicine maximum above 0.6 mg/day, may move out of the literal scope of claim 1. Whether that is permitted clinically or labeled is a separate operational issue.
How to read the “reduction from intended daily dosage amount” language
Claim 1 does more than recite a number. It requires that the adjusted daily dosage amount is a reduction from an intended daily dosage amount absent ritonavir, using the claim’s table as the comparison frame.
Litigation-style construction impact
- If the alleged infringing regimen is at or below 0.6 mg/day, infringement analysis will still focus on whether the dosing is presented, applied, or justified as the ritonavir-adjusted reduced dose relative to the absence-of-ritonavir intended maxima.
- For products or clinical protocols that avoid that explicit reduction framing, the comparison language may be used to argue non-infringement if the method is practiced without the required dose-adjustment logic tied to the table.
What does the patent landscape look like in the US (family, blocking, and likely claim-level positioning)?
Where this patent likely sits conceptually
US 7,906,519 appears to be a drug-drug interaction dosing IP asset:
- Colchicine is an established FMF medicine.
- Ritonavir is a potent CYP3A/P-gp inhibitor (not cited in the provided claim text, but consistent with the rationale for dose reduction).
- The patent’s novelty is the specific adjusted colchicine maximum when co-administered with ritonavir at 200 mg/day in FMF.
This positions the patent as a narrow, regimen-specific blocker rather than a broad composition-of-matter patent.
How that affects landscape strategy
For FMF drug developers, the likely “landscape” situation in the US is:
- Core FMF colchicine use is not generally monopolized for all comers because colchicine is off-patent and widely used.
- The enforceable leverage is the interaction-specific dose ceiling plus the ritonavir dose condition.
So, around this patent, the landscape generally becomes about:
- dosing instructions,
- clinical protocols,
- labeling language,
- and whether alternative regimens avoid the specific ritonavir-dose and/or colchicine maximum.
Claim 1 is likely the anchor. What other claims typically do (and what is missing here)?
You provided only Claim 1 text. In a typical dosing-adjustment patent set, dependent claims often:
- further limit age bands,
- specify additional ritonavir dosing schedules or patient subgroups,
- specify particular dosage forms (tablets, capsules),
- or tie the method to titration and stopping rules.
However, without the remaining claims (2..n), a complete US-claim chart cannot be produced. Under your constraints, this analysis therefore focuses on Claim 1 as the operative scope you supplied.
What competitor actions will map to the claim?
Below are practical “action-to-claim” mappings grounded solely in Claim 1’s limitations.
Practices likely within scope
- Prescribing oral colchicine to FMF patients concurrently with ritonavir 200 mg/day
- Setting the adjusted daily colchicine maximum at or below 0.6 mg/day
- Documenting the regimen as a reduction versus intended colchicine dosing absent ritonavir using the claim’s provided maxima framework
Practices likely outside scope (literal)
- Using ritonavir doses other than 200 mg/day as the concomitant condition
- Setting colchicine dosing such that the adjusted daily maximum exceeds 0.6 mg/day
- Using non-oral colchicine administration
Practices with potential factual disputes
- Regimens that hover around the 0.6 mg/day maximum with variable patient-by-patient dosing
- Off-label ritonavir dosing variations where prescribers argue equivalence to 200 mg/day
Key Takeaways
- US 7,906,519 (Claim 1) is a regimen-specific FMF treatment method: oral colchicine with concomitant ritonavir 200 mg/day and an adjusted colchicine maximum of 0.6 mg/day.
- The patent’s actionable boundary is two numerical tripwires: ritonavir at 200 mg/day and colchicine ceiling at 0.6 mg/day.
- The “reduction from intended daily dosage amount absent ritonavir” language imports the claim’s embedded usual maximum dosing comparison table, anchoring how the adjusted dosing must be framed as a reduction.
- For US product and clinical protocol planning, the patent acts like a narrow blocker aimed at interaction-driven dosing instructions, not a broad monopoly on colchicine for FMF.
FAQs
1) Does Claim 1 protect colchicine as a product?
No. It protects a method of treating FMF using oral colchicine under a specific concomitant ritonavir condition with a specified adjusted maximum dose.
2) What dosing number matters most?
The maximum adjusted colchicine dosage is 0.6 mg per day when ritonavir is 200 mg/day.
3) Are all ritonavir doses covered?
Claim 1 requires ritonavir 200 mg/day, so the scope is tied to that specific concomitant dose.
4) Does age change the ritonavir-concomitant colchicine ceiling?
In the provided Claim 1 text, the ritonavir-concomitant operative ceiling is 0.6 mg/day across the regimen; the age table is used to define the “absence of ritonavir” intended maxima comparison.
5) Does the claim require a particular colchicine form?
In Claim 1 text provided, the requirement is oral administration; no specific formulation is stated in what you supplied.
References
[1] United States Patent 7,906,519. Claim 1 text as provided in the prompt.
